Median effective concentration of ropivacaine for preoperative analgesia under ultrasound-guided supra-inguinal fascia Iliaca compartment block in hip fracture patients

超声引导下髂前上筋膜间隙阻滞术中,罗哌卡因用于髋部骨折患者术前镇痛的中位有效浓度

阅读:1

Abstract

Ultrasound-guided supra-inguinal fascia iliaca compartment block (FICB) is increasingly used for preoperative analgesia in elderly hip fracture patients. However, the median effective concentration (50% effective concentration, EC(50)) of ropivacaine required for supra-inguinal FICB for preoperative analgesia has not been determined. This study was designed to evaluate the EC(50) of 30 mL ropivacaine to maintain preoperative analgesia for at least 24 h. Twenty-eight consecutive patients aged 75 years or older with acute hip fracture were enrolled. All patients received 30 mL ropivacaine for preoperative analgesia. Dixon's up-and-down sequential method was used to determine the concentration of ropivacaine. The initial concentration was 0.35%. Successful analgesia was defined as a Numerical Rating Scale (NRS) score for pain less than 4 during movement within the first 24 h after the block. The concentration in each subsequent patient was determined by the response of the previous patient, and concentrations were adjusted at 0.025% intervals. The 50% and 95% effective concentrations (EC(50), and EC(95)) of ropivacaine were calculated using probit regression. The EC(50) and EC(95) of 30 mL ropivacaine for at least 24-hours effective preoperative analgesia via ultrasound-guided supra-inguinal FICB were 0.248% (95% confidence interval [CI], 0.233-0.262%) and 0.276% (95% CI, 0.262-0.343%), respectively. No adverse events occurred. A single dose of ropivacaine was found to provide effective preoperative analgesia via ultrasound-guided supra-inguinal FICB in elderly patients with hip fracture. The EC(50) (95% CI) of 30 mL ropivacaine for preoperative analgesia lasting at least 24 h was 0.248% (0.233-0.262%).Trial Registration: This trial was registered on UMIN Center Clinical Trials Register (registration number UMIN000050676, date of first trial registration 25/03/2023).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。